Not applicableNot Yet RecruitingNCT07724886What this trial is testingRole of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBCWho this might be right forBladder Cancer Chinese University of Hong Kong 732
Large-scale testing (Phase 3)Active Not RecruitingNCT05243550What this trial is testingSingle-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerWho this might be right forBladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder UroGen Pharma Ltd. 240
Large-scale testing (Phase 3)Ended earlyNCT01410565What this trial is testingEfficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerWho this might be right forBladder Cancer Spectrum Pharmaceuticals, Inc 66
Early research (Phase 1)Active Not RecruitingNCT06253845What this trial is testingStudy of CG0070 After Transurethral Resection in Patients With IR NMIBCWho this might be right forNon-muscle Invasive Bladder Cancer H. Lee Moffitt Cancer Center and Research Institute 20
Not applicableNot Yet RecruitingNCT07749924What this trial is testingActive Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBCWho this might be right forBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC) Tianjin Medical University Second Hospital 670
Large-scale testing (Phase 3)Looking for participantsNCT06510374What this trial is testingTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerWho this might be right forIntermediate Risk Non-Muscle Invasive Bladder Cancer Ferring Pharmaceuticals 454
Not applicableNot Yet RecruitingNCT07817173What this trial is testingFeasibility of HISA During TURBT for NMIBCWho this might be right forBladder CancerBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Non-muscle Invasive Bladder Cancer (NMIBC)+6 more CAMC Health System 40
Not applicableApproved For MarketingNCT06877676What this trial is testingPre-Approval Expanded Access Study for TAR-200 Treating Physician UseWho this might be right forNon-Muscle Invasive Bladder Neoplasms Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Study completedNCT02343614What this trial is testingCelecoxib for the Treatment of Non-muscle Invasive Bladder CancerWho this might be right forNon Muscle Invasive Bladder Cancer Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari 58
Not applicableUnknownNCT05146635What this trial is testingOptimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled TrialWho this might be right forBladder Cancer Mansoura University 110
Not applicableUnknownNCT05626101What this trial is testingSafety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized StudyWho this might be right forNon-muscle-invasive Bladder Cancer Al-Azhar University 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827612What this trial is testingVepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerWho this might be right forUrinary Bladder NeoplasmsUrologic NeoplasmsReceptor, Fibroblast Growth Factor, Type 3 Eli Lilly and Company 161
Post-approval studies (Phase 4)Study completedNCT02214602What this trial is testingValue of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder CancerWho this might be right forCarcinoma of Urinary Bladder, Superficial Mansoura University 240
Large-scale testing (Phase 3)Active Not RecruitingNCT06111235What this trial is testingAdjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTWho this might be right forNon Muscle Invasive Bladder CancerUrologic CancerBladder Cancer+1 more CG Oncology, Inc. 367
Testing effectiveness (Phase 2)Study completedNCT03558503What this trial is testingA Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerWho this might be right forBladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder UroGen Pharma Ltd. 63
Testing effectiveness (Phase 2)Looking for participantsNCT06971614What this trial is testingT3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBCWho this might be right forNonmuscle-invasive Bladder Cancer ImmVira Pharma Co. Ltd 160
Large-scale testing (Phase 3)Looking for participantsNCT07804056What this trial is testingInvestigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder CancerWho this might be right forUrinary Bladder NeoplasmsNon-muscle Invasive Bladder Cancer (NMIBC) Hamlet Pharma AB 194
Large-scale testing (Phase 3)Not Yet RecruitingNCT07198451What this trial is testingEfficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized TrialWho this might be right forNon Muscle Invasive Bladder Cancer Shanghai University of Traditional Chinese Medicine 320
Not applicableLooking for participantsNCT06991868What this trial is testingProspective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)Who this might be right forNMIBCMIBCUTUC Peking University First Hospital 300
Not applicableEnded earlyNCT04412070What this trial is testingAssessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC PatientsWho this might be right forBladder Cancer Hopital Foch 20